Literature DB >> 8271352

Liver dysfunction and energy source: results of a randomized clinical trial.

C E Buchmiller1, R L Kleiman-Wexler, K S Ephgrave, B Booth, C E Hensley.   

Abstract

Controversy still exists regarding the role of the carbohydrate:fat ratio on liver function abnormalities associated with the administration of total parenteral nutrition (TPN). We designed a prospective clinical trail comparing standard carbohydrate-based TPN (8.5% amino acids, 50% dextrose, 7.5% of total calories from lipids) with an isocaloric lipid-based TPN (8.5% amino acids, 30% dextrose, 40% of total calories from lipids) in 43 patients exclusively receiving TPN > or = 2 weeks. Energy needs were calculated as basal energy expenditure x 1.5. The mean daily calorie intake for patients who obtained carbohydrate-based TPN (CHO) was 2227 kcal, whereas the lipid-based TPN (LIP-CHO) group achieved a mean of 2310 kcal. Patients with preexisting liver disease were excluded. There was no significant difference in age or diagnosis between the groups. We monitored total bilirubin, direct bilirubin, alkaline phosphatase, gamma-glutamyl transferase, lactic dehydrogenase, serum glutamic oxaloacetic transaminase, and serum glutamic pyruvic transaminase. Initial liver-associated tests did not vary significantly between groups. Group mean values after 2 weeks of TPN were significantly different for total bilirubin (1.5 mg/dL in the CHO group compared with 0.7 in the LIP-CHO group, p < .05) and direct bilirubin (0.8 mg/dL in the CHO group compared with 0.3 mg/dL in the mixed substrate group, p < .05). Differences in mean values between groups were also noted for serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, and lactic dehydrogenase. In conclusion, this prospective trial reveals that the use of a balanced energy source TPN solution prevents the abnormalities in liver-associated tests commonly associated with TPN.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8271352     DOI: 10.1177/0148607193017004301

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  8 in total

Review 1.  Hepatobiliary abnormalities and parenteral nutrition.

Authors:  B S Tomar
Journal:  Indian J Pediatr       Date:  2000-09       Impact factor: 1.967

Review 2.  Nutritional support for liver disease.

Authors:  Ronald L Koretz; Alison Avenell; Timothy O Lipman
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Glucose-lipid ratio is a determinant of nitrogen balance during total parenteral nutrition in critically ill patients: a prospective, randomized, multicenter blind trial with an intention-to-treat analysis.

Authors:  P Boulétreau; D Chassard; B Allaouchiche; J C Dumont; C Auboyer; M Bertin-Maghit; H Bricard; R Ecochard; J Rangaraj; C Chambrier; C Schneid; L Cynober
Journal:  Intensive Care Med       Date:  2005-08-24       Impact factor: 17.440

4.  Liver dysfunction associated with artificial nutrition in critically ill patients.

Authors:  Teodoro Grau; Alfonso Bonet; Mercedes Rubio; Dolores Mateo; Mercé Farré; José Antonio Acosta; Antonio Blesa; Juan Carlos Montejo; Abelardo García de Lorenzo; Alfonso Mesejo
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

5.  Olive Oil and Soybean Oil Based Intravenous Lipid Emulsions, Liver Biochemistry and Clinical Outcomes.

Authors:  Fabio Araujo; Tanis R Fenton; Sara Lukmanji; Maitreyi Raman
Journal:  Nutrients       Date:  2018-05-23       Impact factor: 5.717

6.  The role of intestinal transplantation in the management of intestinal failure.

Authors:  J P Fryer
Journal:  Curr Gastroenterol Rep       Date:  2001-08

7.  Parenteral Nutrition Associated Hepatic Steatosis and NAFLD Intersect at AMPK.

Authors:  Gregory Guthrie
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-07-07

Review 8.  Liver disease secondary to intestinal failure.

Authors:  Bassam Abu-Wasel; Michele Molinari
Journal:  Biomed Res Int       Date:  2014-01-15       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.